Vericel (VCEL) Stock Could Be 37.3% Undervalued After Earnings Beat And Fund Buying

Simply Wall St.

Jun 22

Vericel (VCEL) has drawn fresh attention after institutional holders such as BlackRock and State Street lifted their positions, and the company reported quarterly earnings per share that came in above...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2645483900"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2645483900\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2645483900?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-06-22 09:19","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645483900","market":"nz","top_or_hot":-1,"title":"Vericel (VCEL) Stock Could Be 37.3% Undervalued After Earnings Beat And Fund Buying","media":"Simply Wall St.","content":"<div>\n<p>Vericel (VCEL) has drawn fresh attention after institutional holders such as BlackRock and State Street lifted their positions, and the company reported quarterly earnings per share that came in above...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vcel/vericel/news/vericel-vcel-stock-could-be-373-undervalued-after-earnings-b\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Vericel (VCEL) Stock Could Be 37.3% Undervalued After Earnings Beat And Fund Buying</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVericel (VCEL) Stock Could Be 37.3% Undervalued After Earnings Beat And Fund Buying\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-22 09:19 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vcel/vericel/news/vericel-vcel-stock-could-be-373-undervalued-after-earnings-b><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Vericel (VCEL) has drawn fresh attention after institutional holders such as BlackRock and State Street lifted their positions, and the company reported quarterly earnings per share that came in above...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vcel/vericel/news/vericel-vcel-stock-could-be-373-undervalued-after-earnings-b\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VCEL","symbol_name":"Vericel Corporation","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vcel/vericel/news/vericel-vcel-stock-could-be-373-undervalued-after-earnings-b","article_id":"2645483900","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-vcel/vericel/news/vericel-vcel-stock-could-be-373-undervalued-after-earnings-b","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2645483900","pubTimestamp":1782091144,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Vericel (VCEL) has drawn fresh attention after institutional holders such as BlackRock and State Street lifted their positions, and the company reported quarterly earnings per share that came in above market expectations.\nSee our latest analysis for Vericel.\nVericel's share price has picked up momentum recently, with a 1-day share price return of 2.48%, 7-day return of 7.05%, and 90-day return of 23.57%. This comes even though the 1-year total shareholder return declined 4.57% and the 5-year...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"VCEL":"Vericel Corporation"},"translate_title":"在盈利超出预期和基金购买后，Vericel(VCEL)股票可能被低估37.3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VCEL":1.5},"content_text":"Vericel (VCEL) has drawn fresh attention after institutional holders such as BlackRock and State Street lifted their positions, and the company reported quarterly earnings per share that came in above market expectations. See our latest analysis for Vericel. Vericel's share price has picked up momentum recently, with a 1-day share price return of 2.48%, 7-day return of 7.05%, and 90-day return of 23.57%. This comes even though the 1-year total shareholder return declined 4.57% and the 5-year total shareholder return fell 40.5%. If Vericel's recent move has you rethinking growth ideas in healthcare, this could be a good moment to see what else is out there via our screener of 40 healthcare AI stocks With institutional holders leaning in, earnings per share ahead of expectations and Vericel trading below the average analyst price target, is this a genuine mispricing or is the market already accounting for future growth? AdvertisementMost Popular Narrative: 37.3% Undervalued On the most followed narrative, Vericel's fair value of $64.00 sits well above the last close at $40.10, setting up a bullishly skewed story.  Planned MACI expansion outside the U.S., starting with a targeted U.K. launch and an addressable MACI Ankle market estimated at more than US$1b, introduces additional revenue streams that can scale on top of an already profitable base and support long term earnings growth.  Read the complete narrative. Curious what underpins that $64.00 fair value for Vericel? The narrative leans on expectations for faster earnings growth, higher margins and a richer future earnings multiple. The exact mix of those assumptions may surprise you. Result: Fair Value of $64.00 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, the bullish Vericel case still hinges on MACI maintaining pricing and surgeon uptake, and on Burn Care contracts such as potential BARDA stockpiling materializing as hoped. Find out about the key risks to this Vericel narrative. Another View on Vericel's Valuation The bullish narrative frames Vericel as undervalued at a fair value of $64.00, but the current P/E of 95.4x tells a different story. That is far above both the peer average of 14.3x and a fair ratio of 27.5x. This points to meaningful valuation risk if sentiment cools. If you lean on earnings multiples rather than narratives, this kind of gap can matter a lot for your risk tolerance, especially when the market has alternatives priced closer to their fair ratio. How comfortable are you paying such a premium for Vericel today? See what the numbers say about this price — find out in our valuation breakdown. NasdaqGM:VCEL P/E Ratio as at Jun 2026Next Steps Given the mixed signals around Vericel, the real question is how you weigh the upside story against the concerns on the table. Move quickly and review the data in detail to make up your own mind using the 2 key rewards and 1 important warning sign. Looking for more investment ideas beyond Vericel? If Vericel has sharpened your focus on valuation, consider your next move carefully by lining up fresh stock ideas with solid fundamentals, income potential and controlled risk.  Target potential bargains early by reviewing the screener containing 19 high quality undiscovered gems before other investors spot them. Strengthen your core holdings by scanning the solid balance sheet and fundamentals stocks screener (48 results) for companies with sturdier financial foundations. Dial back volatility pressure by focusing on the 65 resilient stocks with low risk scores and keeping your watchlist aligned with your risk comfort zone.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}